InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in ...

AbbVie's Emrelis is the first non-small cell lung cancer therapy approved for patients with high c-Met expression levels who ...

Exelixis delivers a strong Q1 performance with raised 2025 guidance, robust Cabometyx sales, and share buybacks. Read the ...

Gachon University has divulged quinoxaline compounds acting as proto-oncogene tyrosine-protein kinase receptor Ret (RET; CDHF12; PTC) and its mutant inhibitors reported to be useful for the treatment ...

New medication appears to be safer and more effective than standard therapy, according to trial led by Chinese and US ...

In its 15th year, Verastem Oncology has gained its first FDA approval, winning an accelerated nod for the combination ...

Drug resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, occurring via secondary mutations or bypass pathways, is frequent among non-small-cell lung cancer patients.

The Congress of Neurological Surgeons (CNS) has updated its guidelines on using emerging therapies to treat metastatic brain ...

Blocking proteins that cause cancer cells to mutate and resist treatment could significantly improve outcomes for some ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...